Paxlovid and Molnupiravir, new antivirals designed to treat COVID-19 at the onset of symptoms, are of great interest to many. I had previously posted information on Molnupiravir, having reviewed two development studies, both employing animal models in testing. The update announced that Molnupiravir had been ethically derived and developed based on the review of these two studies. My assessment was, unfortunately, premature and in error. A third study, submitted in September of 2020 and clearing peer-review in January of 2021, disclosed that humanized lung-only mice were used in transfection and testing of Molnupiravir. These mice were humanized using aborted fetal lung and thymus tissue. It is remarkable that three separate development efforts, all seeking to do the same thing, were undertaken in the development of this drug but the fact remains that aborted fetal tissue was employed in one of the studies.

The development of Paxlovid was documented initially in September of 2020 and was updated with new results shortly after the original submission. This study described the use of several in vitro processes using MRC-5 cell lines and Vero-6 cell lines.

It is clear that these new antivirals, yet to be authorized for use, are morally compromised by the use of aborted fetal tissue and cell lines in their development.